
Chinese biopharmaceutical company founded in January 2013 and based in the Suzhou Industrial Park in Jiangsu, discovering, acquiring, developing and commercialising innovative small molecule drugs. Concentrates on three strategic therapeutic areas - viral infection, neuropsychiatry and reproductive health - and has built a pipeline of nine innovative assets of which two are at the commercialisation stage and four remain preclinical, with LV232 and TPN171 among its core candidates. Filed prospectuses with the Hong Kong Stock Exchange in January and July 2025, received the China Securities Regulatory Commission overseas listing filing notice in June 2025 and passed the listing hearing in October 2025.
Để lại đánh giá